Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Cystectomy Stories

2013-10-08 13:46:09

New ACS NSQIP® study identifies low blood albumin level as an independent risk factor for surgical-related health problems after radical cystectomy Patients with bladder cancer are two times more likely to have complications after a radical cystectomy procedure if they have a biomarker for poor nutritional status before the operation, according to study findings presented today at the 2013 Clinical Congress of the American College of Surgeons. Surgeons from the University of North...

2012-12-19 15:09:08

Patients with muscle invasive bladder cancer may experience less loss of blood and shorter hospital stays as a result of robotic-assisted surgery, new randomized study in the Journal of Urology About 30 percent of the more than 70,000 bladder cancer cases expected in 2012 are muscle invasive. In such cases, radical cystectomy is the preferred treatment. In a pilot trial, a team of investigators assessed the efficacy of open radical cystectomy (ORC) vs. robotic-assisted laparoscopic radical...

2012-11-08 16:28:59

WINSTON-SALEM, N.C., Nov. 8, 2012 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 12/612,606, titled "Cell-Scaffold Constructs." The application includes compositional claims on the construct and cellular elements of Tengion's most advanced product candidate, the Neo-Urinary Conduit(TM), as well as use claims...

2012-10-26 07:23:31

WINSTON-SALEM, N.C., Oct. 26, 2012 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that two patients in the Phase 1 clinical trial of the Company's most advanced product candidate, the Neo-Urinary Conduit(TM), have recently died due to afflictions unrelated to the Neo-Urinary Conduit or the surgical procedure. The fourth patient enrolled in the trial died of metastatic bladder cancer, which had not responded to combination chemotherapy and...

2012-09-10 10:26:58

WINSTON-SALEM, N.C., Sept. 10, 2012 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that it has entered into definitive agreements for a one-month bridge loan with leading investors. The bridge loan is expected to facilitate the issuance of at least $15 million of convertible debt later in September. Tengion also announced today that a sixth patient has been successfully implanted in the ongoing Phase 1 clinical trial of its most advanced...

2012-06-11 02:25:49

WINSTON-SALEM, N.C., June 11, 2012 /PRNewswire/ -- Tengion, Inc. (NASDAQ: TNGN), a leader in regenerative medicine, today announced continued clinical progress on key milestones for the ongoing Phase 1 trial of the Company's most advanced product candidate, the Neo-Urinary Conduit. "We are very pleased to report our continued progress executing on value creating milestones and believe that we are now in a position to accelerate enrollment in the Phase 1 trial of our Neo-Urinary Conduit. The...

2011-11-14 15:05:00

EAST NORRITON, Pa., Nov. 14, 2011 /PRNewswire/ -- Tengion, Inc. (Nasdaq: TNGN) today provided a business update, including announcement of a restructuring plan, and reported its financial results for the third quarter ended September 30, 2011. The restructuring plan is designed to fund the Company's lead development programs through key milestones in 2012 while reducing the Company's anticipated cash utilization. As a result of this restructuring, the Company expects to have sufficient...

2011-09-13 07:30:00

EAST NORRITON, Pa., Sept. 13, 2011 /PRNewswire/ -- Tengion, Inc. (Nasdaq: TNGN) today announced that it has reinitiated enrollment of patients in the ongoing initial clinical trial of its lead product candidate, the Neo-Urinary Conduit(TM), which is being evaluated in bladder cancer patients requiring a urinary diversion following bladder removal (cystectomy). "We are pleased to resume screening procedures to enroll the next patient in our ongoing trial," said Sunita Sheth, M.D., Chief...

2011-06-13 15:30:00

EAST NORRITON, Pa., June 13, 2011 /PRNewswire/ -- Tengion, Inc. (Nasdaq: TNGN) today provided an update on the clinical trial of the Company's lead clinical product candidate, the Neo-Urinary Conduit(TM), for use in bladder cancer patients requiring a urinary diversion following bladder removal (cystectomy). Tengion is continuing to work with investigators to optimize the surgical approach as part of its ongoing clinical trial of the Neo-Urinary Conduit in patients with bladder cancer and...

2011-05-17 15:05:00

CHADDS FORD, Pa. and BELLEVILLE, Ontario, May 17, 2011 /PRNewswire/ -- Endo Pharmaceuticals and Bioniche Life Sciences today presented Phase III trial results for the intravesical formulation of Mycobacterial cell wall-DNA complex (MCC), known as Urocidin(TM), during a podium presentation at the 2011 American Urological Association annual meeting in Washington, D.C. The preliminary results from the interim analysis of this prospective trial indicate that Urocidin(TM) may provide an...